The design of novel metronidazole benzoate structures: exploring stoichiometric diversity

The use of supramolecular synthons as a strategy to control crystalline structure is a crucial factor in developing new solid forms with physicochemical properties optimized by design. However, to achieve this objective, it is necessary to understand the intermolecular interactions in the context of crystal packing. The feasibility of a given synthon depends on its flexibility to combine the drug with a variety of coformers. In the present work, the imidazole–hydroxy synthon is investigated using as the target molecule benzoylmetronidazole [BZMD; systematic name 2‐(2‐methyl‐5‐nitro‐1H‐imidazol‐1‐yl)ethyl benzoate], whose imidazole group seems to be a suitable acceptor for hydrogen bonds. Thus, coformers with carboxylic acid and phenol groups were chosen. According to the availability of binding sites presented in the coformer, and considering the proposed synthon and hydrogen‐bond complementarity as major factors, different drug–coformer stoichiometric ratios were explored (1:1, 2:1 and 3:1). Thirteen new solid forms (two salts and eleven cocrystals) were produced, namely BZMD–benzoic acid (1/1), C₁₃H₁₃N₃O₄·C₇H₆O₂, BZMD–β‐naphthol (1/1), C₁₃H₁₃N₃O₄·C₁₀H₈O, BZMD–4‐methoxybenzoic acid (1/1), C₁₃H₁₃N₃O₄·C₈H₈O₃, BZMD–3,5‐dinitrobenzoic acid (1/1), C₁₃H₁₃N₃O₄·C₇H₄N₂O₆, BZMD–3‐aminobenzoic acid (1/1), C₁₃H₁₃N₃O₄·C₇H₇NO₂, BZMD–salicylic acid (1/1), C₁₃H₁₃N₃O₄·C₇H₆O₃, BZMD–maleic acid (1/1) {as the salt 1‐[2‐(benzoyloxy)ethyl]‐2‐methyl‐5‐nitro‐1H‐imidazol‐3‐ium 3‐carboxyprop‐2‐enoate}, C₁₃H₁₄N₃O₄⁺·C₄H₃O₄^?, BZMD–isophthalic acid (1/1), C₁₃H₁₃N₃O₄·C₈H₆O4, BZMD–resorcinol (2/1), 2C₁₃H₁₃N₃O₄·C₆H₆O₂, BZMD–fumaric acid (2/1), C₁₃H₁₃N₃O₄·0.5C₄H₄O₄, BZMD–malonic acid (2/1), 2C₁₃H₁₃N₃O₄·C₃H₂O₄, BZMD–2,6‐dihydroxybenzoic acid (1/1) {as the salt 1‐[2‐(benzoyloxy)ethyl]‐2‐methyl‐5‐nitro‐1H‐imidazol‐3‐ium 2,6‐dihydroxybenzoate}, C₁₃H₁₄N₃O₄⁺·C₇H₅O₄^?, and BZMD–3,5‐dihydroxybenzoic acid (3/1), 3C₁₃H₁₃N₃O₄·C₇H₆O₄, and their crystalline structures elucidated, confirming the robustness of the selected synthon.     

Conformational studies of hydantoin‐5‐acetic acid and orotic acid

Hydantoin‐5‐acetic acid [2‐(2,5‐dioxoimidazolidin‐4‐yl)acetic acid] and orotic acid (2,6‐dioxo‐1,2,3,6‐tetrahydropyrimidine‐4‐carboxylic acid) each contain one rigid acceptor–donor–acceptor hydrogen‐bonding site and a flexible side chain, which can adopt different conformations. Since both compounds may be used as coformers for supramolecular complexes, they have been crystallized in order to examine their conformational preferences, giving solvent‐free hydantoin‐5‐acetic acid, C₅H₆N₂O₄, (I), and three crystals containing orotic acid, namely, orotic acid dimethyl sulfoxide monosolvate, C₅H₄N₂O₄·C₂H₆OS, (IIa), dimethylammonium orotate–orotic acid (1/1), C₂H₈N⁺·C₅H₃N₂O₄⁻·C₅H₄N₂O₄, (IIb), and dimethylammonium orotate–orotic acid (3/1), 3C₂H₈N⁺·3C₅H₃N₂O₄⁻·C₅H₄N₂O₄, (IIc). The crystal structure of (I) shows a three‐dimensional network, with the acid function located perpendicular to the ring. Interestingly, the hydroxy O atom acts as an acceptor, even though the carbonyl O atom is not involved in any hydrogen bonds. However, in (IIa), (IIb) and (IIc), the acid functions are only slightly twisted out of the ring planes. All H atoms of the acidic functions are directed away from the rings and, with respect to the carbonyl O atoms, they show an antiperiplanar conformation in (I) and synperiplanar conformations in (IIa), (IIb) and (IIc). Furthermore, in (IIa), (IIb) and (IIc), different conformations of the acid O=C—C—N torsion angle are observed, leading to different hydrogen‐bonding arrangements depending on their conformation and composition.     

Synthon preference in a hydrated β‐resorcylic acid structure and its cocrystal with thymine

Multicomponent crystals or cocrystals play a significant role in crystal engineering, the main objective of which is to understand the role of intermolecular interactions and to utilize such understanding in the design of novel crystal structures. Molecules possessing carboxylic acid and amide functional groups are good candidates for forming cocrystals. β‐Resorcylic acid monohydrate, C₇H₆O₄·H₂O, (I), crystallizes in the triclinic space group P with one β‐resorcylic acid molecule and one water molecule in the asymmetric unit. The cocrystal thymine–β‐resorcylic acid–water (1/1/1), C₅H₆N₂O₂·C₇H₆O₄·H₂O, (II), crystallizes in the orthorhombic space group Pca2₁, with one molecule each of thymine, β‐resorcylic acid and water in the asymmetric unit. All available donor and acceptor atoms in (I) and (II) are utilized for hydrogen bonding. The acid and amide functional groups are well known for the formation of self‐complementary acid–acid and amide–amide homosynthons. In (I), an acid–acid homosynthon is observed, while in (II), an amide–acid heterosynthon is present. In (I), the β‐resorcylic acid molecule exhibits the expected intramolecular S(6) motif between the hydroxy and carbonyl O atoms, and an intermolecular R₂²(8) dimer motif between the carboxylic acid groups; only the former motif is observed in (II). The water solvent molecule in (I) propagates the discrete dimers into two‐dimensional hydrogen‐bonded sheets. In (II), thymine and β‐resorcylic acid molecules do not form self‐complementary amide–amide and acid–acid homosynthons; instead, a thymine–β‐resorcylic acid heterosynthon is observed. With the help of the water molecule, this heterosynthon is aggregated into a three‐dimensional hydrogen‐bonded network. The absence of thymine base pairing in (II) might be linked to the availability of additional functional groups and the preference of the donor and acceptor hydrogen‐bond combinations.     

Cocrystals of the antibiotic trimethoprim with glutarimide and 3,3‐dimethylglutarimide held together by three hydrogen bonds

The antibiotic trimethoprim [5‐(3,4,5‐trimethoxybenzyl)pyrimidine‐2,4‐diamine] was cocrystallized with glutarimide (piperidine‐2,6‐dione) and its 3,3‐dimethyl derivative (4,4‐dimethylpiperidine‐2,6‐dione). The cocrystals, viz. trimethoprim–glutarimide (1/1), C₁₄H₁₈N₄O₃·C₅H₇NO₂, (I), and trimethoprim–3,3‐dimethylglutarimide (1/1), C₁₄H₁₈N₄O₃·C₇H₁₁NO₂, (II), are held together by three neighbouring hydrogen bonds (one central N—H...N and two N—H...O) between the pyrimidine ring of trimethoprim and the imide group of glutarimide, with an ADA/DAD pattern (A = acceptor and D = donor). These heterodimers resemble two known cocrystals of trimethoprim with barbituric acid and its 5,5‐diethyl derivative. Trimethoprim shows a conformation in which the planes of the pyrimidine and benzene rings are approximately perpendicular to one another. In its glutarimide coformer, five of the six ring atoms lie in a common plane; the C atom opposite the N atom deviates by about 0.6 Å. The crystal packing of each of the two cocrystals is characterized by an extended network of hydrogen bonds and contains centrosymmetrically related trimethoprim homodimers formed by a pair of N—H...N hydrogen bonds. This structural motif occurs in five of the nine published crystal structures in which neutral trimethoprim is present.     

3‐Cyano‐6‐hydroxy‐4‐methyl‐2‐pyridone: two new pseudopolymorphs and two cocrystals with products of an in situ nucleophilic aromatic substitution

Four crystal structures of 3‐cyano‐6‐hydroxy‐4‐methyl‐2‐pyridone (CMP), viz. the dimethyl sulfoxide monosolvate, C₇H₆N₂O₂·C₂H₆OS, (1), the N,N‐dimethylacetamide monosolvate, C₇H₆N₂O₂·C₄H₉NO, (2), a cocrystal with 2‐amino‐4‐dimethylamino‐6‐methylpyrimidine (as the salt 2‐amino‐4‐dimethylamino‐6‐methylpyrimidin‐1‐ium 5‐cyano‐4‐methyl‐6‐oxo‐1,6‐dihydropyridin‐2‐olate), C₇H₁₃N₄⁺·C₇H₅N₂O₂⁻, (3), and a cocrystal with N,N‐dimethylacetamide and 4,6‐diamino‐2‐dimethylamino‐1,3,5‐triazine [as the solvated salt 2,6‐diamino‐4‐dimethylamino‐1,3,5‐triazin‐1‐ium 5‐cyano‐4‐methyl‐6‐oxo‐1,6‐dihydropyridin‐2‐olate–N,N‐dimethylacetamide (1/1)], C₅H₁₁N₆⁺·C₇H₅N₂O₂⁻·C₄H₉NO, (4), are reported. Solvates (1) and (2) both contain the hydroxy group in a para position with respect to the cyano group of CMP, acting as a hydrogen‐bond donor and leading to rather similar packing motifs. In cocrystals (3) and (4), hydrolysis of the solvent molecules occurs and an in situ nucleophilic aromatic substitution of a Cl atom with a dimethylamino group has taken place. Within all four structures, an R₂²(8) N—H...O hydrogen‐bonding pattern is observed, connecting the CMP molecules, but the pattern differs depending on which O atom participates in the motif, either the ortho or para O atom with respect to the cyano group. Solvents and coformers are attached to these arrangements via single‐point O—H...O interactions in (1) and (2) or by additional R₄⁴(16) hydrogen‐bonding patterns in (3) and (4). Since the in situ nucleophilic aromatic substitution of the coformers occurs, the possible Watson–Crick C–G base‐pair‐like arrangement is inhibited, yet the cyano group of the CMP molecules participates in hydrogen bonds with their coformers, influencing the crystal packing to form chains.     

Sulfur as hydrogen‐bond acceptor in cocrystals of 2‐thio‐modified thymine

Doubly and triply hydrogen‐bonded supramolecular synthons are of particular interest for the rational design of crystal and cocrystal structures in crystal engineering since they show a high robustness due to their high stability and good reliability. The compound 5‐methyl‐2‐thiouracil (2‐thiothymine) contains an ADA hydrogen‐bonding site (A = acceptor and D = donor) if the S atom is considered as an acceptor. We report herein the results of cocrystallization experiments with the coformers 2,4‐diaminopyrimidine, 2,4‐diamino‐6‐phenyl‐1,3,5‐triazine, 6‐amino‐3H‐isocytosine and melamine, which contain complementary DAD hydrogen‐bonding sites and, therefore, should be capable of forming a mixed ADA–DAD N—H…S/N—H…N/N—H…O synthon (denoted synthon 3s_{N·S;N·N;N·O}), consisting of three different hydrogen bonds with 5‐methyl‐2‐thiouracil. The experiments yielded one cocrystal and five solvated cocrystals, namely 5‐methyl‐2‐thiouracil–2,4‐diaminopyrimidine (1/2), C₅H₆N₂OS·2C₄H₆N₄, (I), 5‐methyl‐2‐thiouracil–2,4‐diaminopyrimidine–N,N‐dimethylformamide (2/2/1), 2C₅H₆N₂OS·2C₄H₆N₄·C₃H₇NO, (II), 5‐methyl‐2‐thiouracil–2,4‐diamino‐6‐phenyl‐1,3,5‐triazine–N,N‐dimethylformamide (2/2/1), 2C₅H₆N₂OS·2C₉H₉N₅·C₃H₇NO, (III), 5‐methyl‐2‐thiouracil–6‐amino‐3H‐isocytosine–N,N‐dimethylformamide (2/2/1), (IV), 2C₅H₆N₂OS·2C₄H₆N₄O·C₃H₇NO, (IV), 5‐methyl‐2‐thiouracil–6‐amino‐3H‐isocytosine–N,N‐dimethylacetamide (2/2/1), 2C₅H₆N₂OS·2C₄H₆N₄O·C₄H₉NO, (V), and 5‐methyl‐2‐thiouracil–melamine (3/2), 3C₅H₆N₂OS·2C₃H₆N₆, (VI). Synthon 3s_{N·S;N·N;N·O} was formed in three structures in which two‐dimensional hydrogen‐bonded networks are observed, while doubly hydrogen‐bonded interactions were formed instead in the remaining three cocrystals whereby three‐dimensional networks are preferred. As desired, the S atoms are involved in hydrogen‐bonding interactions in all six structures, thus illustrating the ability of sulfur to act as a hydrogen‐bond acceptor and, therefore, its value for application in crystal engineering.     

6‐Propyl‐2‐thiouracil versus 6‐methoxymethyl‐2‐thiouracil: enhancing the hydrogen‐bonded synthon motif by replacement of a methylene group with an O atom

The understanding of intermolecular interactions is a key objective of crystal engineering in order to exploit the derived knowledge for the rational design of new molecular solids with tailored physical and chemical properties. The tools and theories of crystal engineering are indispensable for the rational design of (pharmaceutical) cocrystals. The results of cocrystallization experiments of the antithyroid drug 6‐propyl‐2‐thiouracil (PTU) with 2,4‐diaminopyrimidine (DAPY), and of 6‐methoxymethyl‐2‐thiouracil (MOMTU) with DAPY and 2,4,6‐triaminopyrimidine (TAPY), respectively, are reported. PTU and MOMTU show a high structural similarity and differ only in the replacement of a methylene group (–CH₂–) with an O atom in the side chain, thus introducing an additional hydrogen‐bond acceptor in MOMTU. Both molecules contain an ADA hydrogen‐bonding site (A = acceptor and D = donor), while the coformers DAPY and TAPY both show complementary DAD sites and therefore should be capable of forming a mixed ADA/DAD synthon with each other, i.e. N—H…O, N—H…N and N—H…S hydrogen bonds. The experiments yielded one solvated cocrystal salt of PTU with DAPY, four different solvates of MOMTU, one ionic cocrystal of MOMTU with DAPY and one cocrystal salt of MOMTU with TAPY, namely 2,4‐diaminopyrimidinium 6‐propyl‐2‐thiouracilate–2,4‐diaminopyrimidine–N,N‐dimethylacetamide–water (1/1/1/1) (the systematic name for 6‐propyl‐2‐thiouracilate is 6‐oxo‐4‐propyl‐2‐sulfanylidene‐1,2,3,6‐tetrahydropyrimidin‐1‐ide), C₄H₇N₄⁺·C₇H₉N₂OS⁻·C₄H₆N₄·C₄H₉NO·H₂O, (I), 6‐methoxymethyl‐2‐thiouracil–N,N‐dimethylformamide (1/1), C₆H₈N₂O₂S·C₃H₇NO, (II), 6‐methoxymethyl‐2‐thiouracil–N,N‐dimethylacetamide (1/1), C₆H₈N₂O₂S·C₄H₉NO, (III), 6‐methoxymethyl‐2‐thiouracil–dimethyl sulfoxide (1/1), C₆H₈N₂O₂S·C₂H₆OS, (IV), 6‐methoxymethyl‐2‐thiouracil–1‐methylpyrrolidin‐2‐one (1/1), C₆H₈N₂O₂S·C₅H₉NO, (V), 2,4‐diaminopyrimidinium 6‐methoxymethyl‐2‐thiouracilate (the systematic name for 6‐methoxymethyl‐2‐thiouracilate is 4‐methoxymethyl‐6‐oxo‐2‐sulfanylidene‐1,2,3,6‐tetrahydropyrimidin‐1‐ide), C₄H₇N₄⁺·C₆H₇N₂O₂S⁻, (VI), and 2,4,6‐triaminopyrimidinium 6‐methoxymethyl‐2‐thiouracilate–6‐methoxymethyl‐2‐thiouracil (1/1), C₄H₈N₅⁺·C₆H₇N₂O₂S⁻·C₆H₈N₂O₂S, (VII). Whereas in (I) only an AA/DD hydrogen‐bonding interaction was formed, the structures of (VI) and (VII) both display the desired ADA/DAD synthon. Conformational studies on the side chains of PTU and MOMTU also revealed a significant deviation for cocrystals (VI) and (VII), leading to the desired enhancement of the hydrogen‐bond pattern within the crystal.     

Charge‐transfer complexes of N‐methyl‐, N‐iso­propyl‐, N‐butyl‐ and N‐iso­butyl­carbazole with 3,5‐di­nitro­benzoic acid

In the title four compounds, C₁₃H₁₁N·C₇H₄N₂O₆, (I), C₁₅H₁₅N·C₇H₄N₂O₆, (II), C₁₆H₁₇N·C₇H₄N₂O₆, (III), and C₁₆H₁₇N·C₇H₄N₂O₆, (IV), the donor and acceptor mol­ecules are stacked alternately to form one‐dimensional columns. In (I), the N‐methyl group of the donor is nearly eclipsed with respect to one of the nitro groups of the neighboring acceptor in a column, whereas the N‐iso­propyl, N‐butyl and N‐iso­butyl groups are in anti positions with respect to one of the nitro groups of the neighboring acceptor in compounds (II)–(IV).     

Cocrystallization of two tautomers: 4‐(1‐{[4‐(dimethylamino)benzylidene]hydrazono}ethyl)benzene‐1,3‐diol and 6‐[(E)‐1‐{[4‐(dimethylamino)benzylidene]hydrazino}ethylidene]‐3‐hydroxycyclohexa‐2,4‐dien‐1‐one (1/1)

Two different tautomeric forms of a new Schiff base, C₁₇H₁₉N₃O₂·C₁₇H₁₉N₃O₂, are present in the crystal in a 1:1 ratio, namely the enol–imine form 4‐(1‐{[4‐(dimethylamino)benzylidene]hydrazono}ethyl)benzene‐1,3‐diol and the keto–amine form 6‐[(E)‐1‐{[4‐(dimethylamino)benzylidene]hydrazino}ethylidene]‐3‐hydroxycyclohexa‐2,4‐dien‐1‐one. The tautomers are formed by proton transfer between the hydroxy O atom and the imine N atom and are hydrogen bonded to each other to form a one‐dimensional zigzag chain along the crystallographic b axis via intermolecular hydrogen bonds.     

6‐Chloroisocytosine and 5‐bromo‐6‐methylisocytosine: again,one or two tautomers present in the same crystal?

It is well known that pyrimidin‐4‐one derivatives are able to adopt either the 1H‐ or the 3H‐tautomeric form in (co)crystals, depending on the coformer. As part of ongoing research to investigate the preferred hydrogen‐bonding patterns of active pharmaceutical ingredients and their model systems, 2‐amino‐6‐chloropyrimidin‐4‐one and 2‐amino‐5‐bromo‐6‐methylpyrimidin‐4‐one have been cocrystallized with several coformers and with each other. Since Cl and Br atoms both have versatile possibilities to interact with the coformers, such as via hydrogen or halogen bonds, their behaviour within the crystal packing was also of interest. The experiments yielded five crystal structures, namely 2‐aminopyridin‐1‐ium 2‐amino‐6‐chloro‐4‐oxo‐4H‐pyrimidin‐3‐ide–2‐amino‐6‐chloropyrimidin‐4(3H)‐one (1/3), C₅H₇N₂⁺·C₄H₃ClN₃O⁻·3C₄H₄ClN₃O, (Ia), 2‐aminopyridin‐1‐ium 2‐amino‐6‐chloro‐4‐oxo‐4H‐pyrimidin‐3‐ide–2‐amino‐6‐chloropyrimidin‐4(3H)‐one–2‐aminopyridine (2/10/1), 2C₅H₇N₂⁺·2C₄H₃ClN₃O⁻·10C₄H₄ClN₃O·C₅H₆N₂, (Ib), the solvent‐free cocrystal 2‐amino‐5‐bromo‐6‐methylpyrimidin‐4(3H)‐one–2‐amino‐5‐bromo‐6‐methylpyrimidin‐4(1H)‐one (1/1), C₅H₆BrN₃O·C₅H₆BrN₃O, (II), the solvate 2‐amino‐5‐bromo‐6‐methylpyrimidin‐4(3H)‐one–2‐amino‐5‐bromo‐6‐methylpyrimidin‐4(1H)‐one–N‐methylpyrrolidin‐2‐one (1/1/1), C₅H₆BrN₃O·C₅H₆BrN₃O·C₅H₉NO, (III), and the partial cocrystal 2‐amino‐5‐bromo‐6‐methylpyrimidin‐4(3H)‐one–2‐amino‐5‐bromo‐6‐methylpyrimidin‐4(1H)‐one–2‐amino‐6‐chloropyrimidin‐4(3H)‐one (0.635/1/0.365), C₅H₆BrN₃O·C₅H₆BrN₃O·C₄H₄ClN₃O, (IV). All five structures show R₂²(8) hydrogen‐bond‐based patterns, either by synthon 2 or by synthon 3, which are related to the Watson–Crick base pairs.     

Bis(dimethyl sulfoxide‐S)tetrakis(μ‐p‐hydroxybenzoato‐O:O′)dirhodium(II)–tetrakis(μ‐butyrato‐O:O′)bis(dimethyl sulfoxide‐S)dirhodium(II) cocrystal ethanol disolvate

The title structure, [Rh₂(C₇H₅O₃)₄(C₂H₆OS)₂]·[Rh₂(C₄H₇­O₂)₄(C₂H₆OS)₂]·2C₂H₆O, contains two discrete neutral Rh–Rh dimers cocrystallized as the ethanol disolvate. Each dimer is situated on an inversion center. The butyrate chain displays disorder in one C‐atom position. In each dimer, the di­methyl sulfoxide ligand (dmso) is bound via S, as expected. The ethanol is a hydrogen‐bond acceptor for one p‐hydroxy­benzoate hydroxyl group and acts as a hydrogen‐bond donor to the dmso O atom of a neighboring p‐hydroxy­benzoate dirhodium complex. A third hydrogen bond is formed from the other p‐hydroxy­benzoate hydroxyl group to the dmso O atom of a butyrate–dirhodium complex.     

The first example of a two‐coordinated AuI atom bonded to an FeII atom and an N‐heterocyclic carbene (NHC) ligand

The aurophilicity exhibited by Au^I complexes depends strongly on the nature of the supporting ligands present and the length of the Au–element (Au—E) bond may be used as a measure of the donor–acceptor properties of the coordinated ligands. A binuclear iron–gold complex, [1,3‐bis(2,6‐diisopropylphenyl)imidazol‐2‐ylidene‐2κC²]dicarbonyl‐1κ²C‐(1η⁵‐cyclopentadienyl)gold(I)iron(II)(Au—Fe) benzene trisolvate, [AuFe(C₅H₅)(C₂₇H₃₆N₂)(CO)₂]·3C₆H₆, was prepared by reaction of K[CpFe(CO)₂] (Cp is cyclopentadienyl) with (NHC)AuCl [NHC = 1,3‐bis(2,6‐diisopropylphenyl)imidazol‐2‐ylidene]. In addition to the binuclear complex, the asymmetric unit contains three benzene solvent molecules. This is the first example of a two‐coordinated Au atom bonded to an Fe and a C atom of an N‐heterocyclic carbene.     

The solid‐state 2:1 molecular complex of 1,5:3,7‐dimethano‐1,3,5,7‐benzotetrazonine with hydroquinone

The title compound, 1,5:3,7‐dimethano‐1,3,5,7‐benzotetrazonine–hydroquinone (2/1), 2C₁₁H₁₄N₄·C₆H₆O₂, crystallizes with the hydroquinone molecule located on a center of inversion. In contrast to other hydroquinone–adamanzane adducts, which form extended hydrogen‐bonded networks, in the present case, one hydroquinone molecule is linked to two 1,5:3,7‐dimethano‐1,3,5,7‐benzotetrazonine molecules, forming a 2:1 cluster through O—H...N hydrogen bonds.     

Two terphenyl‐based diol hosts and corresponding solvent inclusions with dimethylformamide and acetonitrile

Having reference to an elongated structural modification of 2,2′‐bis(hydroxydiphenylmethyl)biphenyl, (I), the two 1,1′:4′,1′′‐terphenyl‐based diol hosts 2,2′′‐bis(hydroxydiphenylmethyl)‐1,1′:4′,1′′‐terphenyl, C₄₄H₃₄O₂, (II), and 2,2′′‐bis[hydroxybis(4‐methylphenyl)methyl]‐1,1′:4′,1′′‐terphenyl, C₄₈H₄₂O₂, (III), have been synthesized and studied with regard to their crystal structures involving different inclusions, i.e. (II) with dimethylformamide (DMF), C₄₄H₃₄O₂·C₂H₆NO, denoted (IIa), (III) with DMF, C₄₈H₄₂O₂·C₂H₆NO, denoted (IIIa), and (III) with acetonitrile, C₄₈H₄₂O₂·CH₃CN, denoted (IIIb). In the solvent‐free crystals of (II) and (III), the hydroxy H atoms are involved in intramolecular O—H...π hydrogen bonding, with the central arene ring of the terphenyl unit acting as an acceptor. The corresponding crystal structures are stabilized by intermolecular C—H...π contacts. Due to the distinctive acceptor character of the included DMF solvent species in the crystal structures of (IIa) and (IIIa), the guest molecule is coordinated to the host via O—H...O=C hydrogen bonding. In both crystal structures, infinite strands composed of alternating host and guest molecules represent the basic supramolecular aggregates. Within a given strand, the O atom of the solvent molecule acts as a bifurcated acceptor. Similar to the solvent‐free cases, the hydroxy H atoms in inclusion structure (IIIb) are involved in intramolecular hydrogen bonding, and there is thus a lack of host–guest interaction. As a result, the solvent molecules are accommodated as C—H...N hydrogen‐bonded inversion‐symmetric dimers in the channel‐like voids of the host lattice.     

The proton‐transfer compounds of strychnine with achiral salicylic acids: strychninium 3,5‐dinitro­salicylate and the strychninium 5‐nitro­salicylate bis­(5‐nitro­salicylic acid) adduct

In the crystal structures of the proton‐transfer compounds of strychnine with 3,5‐dinitro­salicylic acid, namely strychninium 3,5‐dinitro­salicylate, C₂₁H₂₃N₂O₂⁺·C₇H₃N₂O₇⁻, (I), and 5‐nitro­salicylic acid, namely strychninium–5‐nitro­salicylate–5‐nitro­salicylic acid (1/1/2), C₂₁H₂₃N₂O₂⁺·C₇H₄NO₅⁻·2C₇H₅NO₅, (II), protonation of one of the N atoms of the strychnine mol­ecule occurs and this group is subsequently involved in inter­molecular hydrogen‐bonding inter­actions. In (I), this is four‐centred, the primary being with an adjacent strychninium carbonyl O‐atom acceptor in a side‐to‐side inter­action giving linear chains. Other inter­actions are with the phenolate and nitro O‐atom acceptors of the anionic species, resulting in a one‐dimensional polymer structure. In (II), the N⁺—H inter­action is three‐centred, the hydrogen bonding involving carboxyl O‐atom acceptors of the anion and both acid adduct species, giving unique discrete hetero‐tetramer units. The structure of (II) also features π‐bonding inter­actions between the two acid adduct mol­ecules.     

Hydrogen‐bonded layered structures in two bis(tert‐butyldimethylsilyloxy)‐substituted cyclic diol derivatives

2,6‐Bis(tert‐butyldimethylsilyloxy)‐9‐oxabicyclo[3.3.1]nonane‐3,7‐diol, C₂₀H₄₂O₅Si₂, (I), and 4,8‐bis(tert‐butyldimethylsilyloxy)‐2,6‐dioxatricyclo[3.3.1^3,7]decane‐1,3‐diol, C₂₀H₄₀O₆Si₂, (II), form layered structures that differ in the way the molecules are connected within each layer. The endocyclic O atom common to both structures plays an active role in the hydrogen‐bonding network, whereas the second oxygen bridge in (II) does not participate in any interaction. This work reports the first structural analysis of two bis(tert‐butyldimethylsilyloxy)‐substituted cyclic diol derivatives and provides insight into the influence of small changes in the molecular structure on the supramolecular aggregation. The unbalanced hydrogen‐bond acceptor/donor ratio, greater in (II) than in (I), does not result in the inclusion of water molecules in the structure.     

Brucine and two solvates

The crystal structures of brucine (2,3‐di­methoxy­strychnidin‐10‐one), C₂₃H₂₆N₂O₄, brucine acetone solvate, C₂₃H₂₆N₂O₄·C₃H₆O, and brucine 2‐propanol solvate dihydrate, C₂₃H₂₆N₂O₄·C₃H₇O·2H₂O, have been determined. Crystals of brucine and its 2‐propanol solvate dihydrate exhibit similar monolayer sheet packing, whereas crystals of the acetone solvate adopt a different mode of packing, as brucine pillars. The solvent appears to control the brucine self‐assembly on the basis of common donor–acceptor properties of the surfaces.     

Charge‐transfer complexes of N‐methyl‐and N‐ethyl­carbazole with 3,5‐di­nitro­benzo­nitrile

In the two title compounds, N‐methyl­carba­zole–3,5‐di­nitro­benzo­nitrile (1/1), C₁₃H₁₁N·C₇H₃N₃O₄, (I), and N‐ethyl­carba­zole–3,5‐di­nitro­benzo­nitrile (1/1), C₁₄H₁₃N·C₇H₃N₃O₄, (II), the donor and acceptor mol­ecules are stacked alternately to form one‐dimensional columns. In (I), the N‐methyl group of the donor is nearly eclipsed with respect to one of the nitro groups of the neighboring acceptor in a column, whereas the N‐ethyl group is anti with respect to the cyano group of the neighboring acceptor in (II).     

catena‐Poly[[[(benzene‐1,3,5‐tricarboxylic acid)(1,10‐phenanthroline)cadmium(II)]‐μ‐oxalato] 1H‐benzotriazole solvate monohydrate]

In the title compound, [Cd(C₂O₄)(C₁₂H₈N₂)(C₉H₆O₆)]·C₆H₅N₃·H₂O, the Cd^II atom has a distorted pentagonal–bipyramidal geometry, defined by two N atoms and five O atoms from bidentate 1,10‐phenanthroline ligands, oxalate ligands and benzene‐1,3,5‐tricarboxylic acid ligands. The oxalate ligands in the asymmetric unit possess inversion symmetry. The triazole molecule is not coordinated to the Cd atom. The structure of the title compound features a one‐dimensional chain running along the crystallographic a axis, and a three‐dimensional supramolecular network is formed via aromatic π–π interactions and hydrogen‐bonding interactions.     

A donor–acceptor compound composed of a di­nuclear zinc(II) complex of a Robson macro­cycle with 8‐methyl­quino­line

A donor–acceptor compound, di­aqua‐1κO,2κO‐[μ‐11,23‐dimethyl‐3,7,15,19‐tetra­aza­tri­cyclo­[19.3.1.1^9,13]hexacosa‐1(25),2,7,9,11,13(26),14,19,21,23‐decaene‐25,­26‐diolato‐1κ⁴N³,N⁷,O²⁵,O²⁶:­2κ⁴N¹⁵,N¹⁹,O²⁵,O²⁶]­dizinc(II) diperchlorate bis(8‐methyl­quinoline) ethanol disolvate, [Zn₂(C₂₄H₂₆N₄O₂)(H₂O)₂](ClO₄)₂·2C₁₀H₉N·2C₂H₆O, obtained by the reaction of a dinuclear zinc(II) complex of a Robson macrocycle (acceptor) and 8‐methyl­quinoline (donor), lies about an inversion centre and the coordination about the unique Zn atom is a distorted square pyramid. The fifth coordination site is occupied by the water mol­ecule, Zn—O = 2.016 (2) Å, and the average macrocyclic Zn—O and Zn—N distances are 2.059 (6) and 2.059 (3) Å, respectively.